| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 124.72 | 69.2% | 32.9% |
| Total Income | 125.54 | 67.8% | 31.1% |
| Expenditure | 139.12 | 40.2% | 15.1% |
| PBT | -15.68 | 35.8% | 37.7% |
| Net Profit | -15.69 | 35.8% | 61.1% |
| OPM | 1.52% | 10.59pp | 53.07pp |
| NPM | -12.49% | 20.14pp | 29.66pp |
| EPS | 7.04 | 38.0% | 134.2% |
Astec Lifesciences Reports Q3FY26 Financial Results: Revenue Growth, Improved Margins, and Positive EBITDA
30 Jan 2026 · 30 Jan, 8:52 pm
Summary
Astec Lifesciences Limited has announced its financial results for the third quarter & nine months ended December 31, 2025. The company reported a consolidated total income of Rs. 125.5 crore in Q3FY26, a significant increase from Rs. 95.7 crore in Q3FY25. The company also reported a consolidated EBITDA of Rs. 4.8 crore in Q3FY26, compared to an EBITDA loss of Rs. 3.8 crore in Q3 FY25. However, the company reported a loss of Rs. 15.7 crore in Q3FY26, although this is still a significant improvement from the loss of Rs. 40.4 crore in Q3FY25.
Key Highlights
- 1
1.3x growth in revenue over Q3 FY25
- 2
1.7x increase in revenue over Q2 FY26
- 3
Improvement in Enterprise margins
- 4
Positive EBITDA of Rs.4.8 crore in Q3 FY26
- 5
Revenue from Operations: Enterprise, Contract Manufacturing & New Products
- 6
Geography Breakdown: Exports, Domestic
Management Comments
Mr. N B Godrej
Chairman, Astec LifeSciences Limited
Astec delivered strong revenue growth, recording 1.3x growth over Q3 FY25 on the back of higher Enterprise volumes and improved offtake in the Contract Manufacturing segment.
Informational and educational content only. Not investment advice.